Abstract: Disclosed herein are methods and systems for controlled ejection of desired material onto surfaces including in single cells using nanopipettes, as well as ejection onto and into cells. Some embodiments are directed to a method and system comprising nanopipettes combined with an xyz controller for depositing a user defined pattern on an arbitrary substrate for the purpose of controlled cell adhesion and growth. Alternate embodiments are directed to a method and system comprising nanopipettes combined with an xyz controller and electronic control of a voltage differential in a bore of the nanopipette electroosmotically injecting material into a cell in a high-throughput manner and with minimal damage to the cell. Yet other embodiments are directed to method and system comprising functionalized nanopipettes combined with scanning ion conductance microscopy for studying molecular interactions and detection of biomolecules inside a single living cell.

Abstract: The invention relates to transgene expression constructs—particularly self inactivating lentiviral vectors—comprising a dendritic cell specific promoter controlling the expression of autoantigen proteins, namely myelin basic protein, proteolipid protein and myelin oligodendrocyte glycoprotein, for use in the therapy of multiple sclerosis.

Abstract: The present invention provides novel agents for broad spectrum influenza neutralization. The present invention provides agents for inhibiting influenza infection by bind to the influenza virus and/or hemagglutinin (HA) polypeptides and/or HA receptors, and reagents and methods relating thereto. The present invention provides a system for analyzing interactions between infolds and the interaction partners that bind to them.

Abstract: Live cells of a microorganism in a test sample are detected by the following steps: a) the step of treating the test sample with a topoisomerase poison and/or a DNA gyrase poison, b) the step of extracting DNA from the test sample, and amplifying a target region of the extracted DNA by PCR, and c) the step of analyzing an amplification product.

Abstract: A screening method is described for selecting patient-specific anti-cancer agents reflecting individual genetic properties, in a precise and rapid manner, using an extremely small amount of cancer cells. Such screening method is useful for development of novel anti-cancer agents and the personalized medical field.

Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.

Abstract: The present invention provides a method for treating Usher's syndrome in a human subject including administering to the human subject an oligonucleotide having 8 to 30 linked nucleosides having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length within exon 3 of an Usher RNA transcript.

Abstract: Image texture feature values are computed for a set of image texture features from an image of an anatomical feature of interest in a subject, and the subject is classified respective to a molecular feature of interest based on the computed image texture feature values. The image texture feature values may be computed from one or more gray level co-occurrence matrices (GLCMs), and the image texture features may include Haralick and/or Tamura image texture features. To train the classifier, reference image texture feature values are computed for at least the set of image texture features from images of the anatomical feature of interest in reference subjects. The reference image texture feature values are divided into different population groups representing different values of the molecular feature of interest, and the classifier is trained to distinguish between the different population groups based on the reference image texture feature values.

Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal recovery and/or renal non-recovery.

Abstract: Methods and apparatus are adapted to wash magnetic particles isolated in a vessel. The methods include providing a vessel with wash liquid and a layer of magnetic particles, providing a probe having aspiration capability, positioning a probe tip above the layer of magnetic particles, aspirating at least some of the wash liquid above the layer, positioning the probe tip below the layer, and aspirating at least some of the wash liquid from below the layer of magnetic particles. The suction may be turned off as the probe tip descends past the layer. A novel magnetic particle washing apparatus are disclosed.

Abstract: Provided are compositions and methods for inhibiting hypoxia-induced damage. The compositions and methods involve the use of one or more agents that can inhibit one or any combination of the genes BCL2L14, BLOC1S2, C20RF42, CPT1A, FBP1, GCNT3, RHOB, SCIN, TACR1 and TNFAIP6. Polynucleotide and non-polynucleotide agents which can be used for inhibiting one or more of the genes are included. The method involves introducing one or more gene inhibiting agents to a cell, tissue, organ, or individual such that formation of hypoxia related damage is inhibited. Kits which contain the agents and printed information about using them for inhibiting hypoxia induced damage are also included.

Abstract: Methods and compositions are provided for treating HIV infection and for inhibiting HIV infection, and for identifying purinergic receptor antagonists or Panx 1 hemi-channel blockers useful therefor. The invention provides a method of treating a mammalian subject having an HIV infection, or suspected of having been exposed to HIV, comprising administering to the mammalian subject an amount of (i) an antagonist of a Panx 1 hemichannel, or (ii) of an inhibitor of a purinergic receptor, effective to inhibit (a) HIV fusion with a target cell, or (b) HIV replication, or (c) HIV entry into a target cell, or two or more of (a), (b) and (c).

Abstract: A method of separating bead substrates includes applying an emulsion to an emulsion-breaking solution. A dispersed phase of the emulsion includes an unbound polynucleotide, a first set of bead substrates and a second set of bead substrates. The unbound polynucleotide includes a segment complementary to a coupling oligonucleotide. The first set of bead substrates includes the coupling oligonucleotide extended to include a segment complementary to a portion of the unbound polynucleotide. The second set of bead substrates includes the coupling oligonucleotide. The emulsion-breaking solution includes an interference probe having a sequence similar to the coupling oligonucleotide or complementary to the coupling oligonucleotide. The method further includes binding beads of the first set of bead substrates to separation substrates and separating unbound beads of the second set of bead substrates from the beads of the first set of bead substrates bound to the separation substrates.

Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.

Abstract: Methods using biomarkers, e.g., serum levels of ST2, to predict risk of developing hypertension, as well as methods for treating subjects to reduce the risk of developing hypertension and methods for selecting and/or stratifying subjects for clinical trials of treatments to reduce the risk of hypertension.

Abstract: Method for detecting a material of interest, usually an antibody or an antigen on a red blood cell, in a liquid, by observing the potential antigen/antibody reaction products in a novel way. Reaction products are deposited on a magnetic substrate and will exhibit different properties depending upon whether or not the antigen/antibody reaction has taken place. An antigen/antibody reaction product adheres tenaciously to itself and the substrate while the deposit of any unreacted magnetically tagged material is weakly adhering and easily disrupted and dislodged under a disruptive force which would be insufficient to dislodge the reacted deposit. This difference in cohesive property provides the means by which a positive result is distinguished from a negative result.

Abstract: A method and apparatus are provided for identifying a biological sample obtained during either paternity screening, genetic screening, prenatal diagnosis, presymptomatic diagnosis, diagnosis to detect the presence of a target microorganism carrier detection analysis, forensic chemical analysis, or diagnosis of a subject to determine whether a subject is afflicted with a particular disease or disorder, or is at risk of developing a particular disorder, wherein the result obtained from the analysis is associated with the unique DNA fingerprint biological barcode of the genotype of the subject being analyzed. The methods and apparatus of the invention have application in the fields of diagnostic medicine, disease diagnosis in animals and plants, identification of genetically inherited diseases in humans, family relationship analysis, forensic analysis, and microbial typing.

Abstract: Reprogrammed somatic cells, methods for reprogramming, reprogramming factors for somatic cells and uses of such factors and cells are described. Nuclear reprogramming factors [NRF] described comprise one or more of a gene product or a polynucleic acid encoding a gene product from a retinoic acid receptor (RAR/RXR) family member, or an agonist or antagonist thereof; a gene product from an Lrh1 family member; or an agonist thereof; retinoic acid or a gene product involved in synthesizing or metabolizing retinoic acid; or an agonist or antagonist thereof; or a gene product that is involved in transporting a retinoic acid family member.

Abstract: Methods for the determination of tissue-specific genetic variation are provided. For example, in certain aspects methods for using iPS cell-derived specific cell types for differential molecular analysis of tissue-specific genetic variation are described.

Abstract: The current invention relates to a method for analysis of a population of micro-organisms (e.g. bacterial population) of different taxonomic groups in an environment suspected to contain said bacteria, primers, primer sets and pair of primer sets suitable for use is such method, and use of such method in determining the effect of external factors like drugs, nutrients and pesticides on bacterial populations of different taxonomic groups.

Abstract: The present invention relates to an improved method for isolating nucleic acids, particularly genomic desoxyribonucleic acid (DNA) from blood.

Abstract: A touch screen user interface for an optical device wherein the touch screen user interface is connected to a controller which controls motion stages permitting the motion stages to re-position, re-size, re-orient or focus the field of view of the optical device in response to commands input from the touch screen user interface.

Abstract: The present application shows the relationship between variations in the amino acid sequence of histone proteins, more specifically the H3.3 protein, and proliferation-associated disorders. Herewith provided are predictive methods, commercial packages, therapeutic methods and screening methods based on this relationship.

Abstract: It is disclosed a pharmaceutical composition containing an oligonuclelotide chelate complex and at least one polypeptide or pegylated polypeptide. The present disclosure also describes additional pharmaceutical compositions and methods for the treatment of diseases including viral infections.

Abstract: Methods and compositions for gene disruption, gene editing or gene stacking within a FAD2 loci by cleaving, in a site directed manner, a location in a FAD2 gene in a soybean cell, to generate a break in the FAD2 gene and then optionally integrating into the break a nucleic acid molecule of interest is disclosed.

Abstract: The present invention provides inventive polypeptides comprising a C terminal RAB binding domain (RabBD) of RAB family interacting proteins (FIPs) stabilized by peptide stapling, and pharmaceutical compositions thereof. Also provided are methods for modulating RAB function comprising contacting an inventive stapled polypeptide with a RAB protein, and methods of treatment associated with modulation of RAB activity. The present invention also provides methods of making the inventive stapled polypeptides by ring closing metathesis of unstapled polypeptide precursors.

Abstract: Example apparatus and methods cause activation of target neural tissue through electrical stimulation of a connected white matter tract to reduce the hyper-excitability of the target neural tissue and thus reduce seizures while preserving memory in humans. Example apparatus and methods apply low frequency (e.g., <10 HZ) electrical stimulation to the forno-dorso-commissure (FDC), detect an electrical signal generated in an area connected to, innervated by, or that can be activated by the FDC in response to the stimulation, and reconfigure the stimulation based on the detected signal and a desired therapeutic effect. The stimulation may be reconfigured to produce an electrical stimulation waveform that will produce the desired therapeutic effect. The desired therapeutic effect may be, for example, reducing hyper-excitability of neural tissue in a target area, reducing hippocampal spikes, reducing seizure odds, or improving recall.

Abstract: The present invention provides a method of enabling the use of long dsRNA for gene silencing in mammalian cells through bacteria, preferably non-pathogenic or therapeutic strains of bacteria. DNA that encodes long double-strand RNAs are transformed into bacteria and processed in the bacterial cells into a mixture of smaller RNA duplexes and then released into the cytoplasm of the target cells, resulting in modulation of gene expression in the target cells. The methods overcome the incompatibility between long strong dsRNA and mammalian cells by eliminating, or mitigating, the non-specific innate immune response. The eukaryotic cells can be mammalian cells or avian cells. The gene of interest can be a mammalian, avian, bacterial, eukaryotic, or viral gene.

Abstract: The present invention is directed to oligonucleotides based on peptide nucleic acid oligonucleotide or an equivalent oligonucleotide analogue, such as morpholino or a locked nucleic acid sequences and the use of such oligonucleotides for the dissociation of higher order structures, including triplex-helix DNA structures, in repeated sequences of DNA in Friedreich's ataxia. The dissociation of such structures may be used in the diagnosis and/or treatment of Friedreich's ataxia. Consequently, the present invention is also directed to a method for diagnosing Friedreich's ataxia and the use of peptide nucleic acid oligonucleotide or an equivalent oligonucleotide analogue, such as morpholino or a locked nucleic acid sequences in the treatment of Friedreich's ataxia. Preferably, the oligonucleotides comprise a sequence selected from the group consisting of (GAA)n, (CTT)n, (JTT)n or a mixed (JTT/CTT)n sequence.

Abstract: The invention provides improved mutagenic plasmids and a method for making and using them. In one embodiment a cyclic mutagenic nucleic acid is replicated to form interlocking, digestibly separable duplex or simplex rings; and then one or more of the interlocked rings are cleaved selectively by means of a restriction enzyme to liberate an intact duplex or simplex ring. The mutagenic plasmids show substantially improved efficiencies in transforming cellular microorganism that are exposed to them.

Abstract: The identification of mutations that are present in a small fraction of DNA templates is essential for progress in several areas of biomedical research. Though massively parallel sequencing instruments are in principle well-suited to this task, the error rates in such instruments are generally too high to allow confident identification of rare variants. We here describe an approach that can substantially increase the sensitivity of massively parallel sequencing instruments for this purpose. One example of this approach, called “Safe-SeqS” for (Safe-Sequencing System) includes (i) assignment of a unique identifier (UID) to each template molecule; (ii) amplification of each uniquely tagged template molecule to create UID-families; and (iii) redundant sequencing of the amplification products. PCR fragments with the same UID are truly mutant (“super-mutants”) if ?95% of them contain the identical mutation.

Abstract: A cell monitoring device includes an outline detecting section that detects edge pixels from a cell image in a captured image of cells arranged in a single layer and generates an edge image including the detected edge pixels; a pigmented region detecting section that detects pixels of a pigmented region of the cell image in the captured image, and generates a pigmented region image including the detected pixels of the pigmented region; and an image merging section that, in a merged image obtained by overlaying the edge image and the pigmented region image together, detects a cell image region and a background image region in the captured image based on the pixel intensity variance and thus detects the cell image region in the captured image.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumor, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer.

Abstract: A reusable composite paramagnetic particle may comprise a paramagnetic core encased by a protective material to which is grafted a tendril layer comprising a plurality of polymeric chains. The polymeric chains may be designed to interact with a microorganism. The interaction between the microorganism and the polymeric chain may be electrostatic. The nanoparticle may be used in a method to isolate or recover microorganisms from solutions using an externally applied magnetic field.

Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.

Abstract: The present invention discloses novel polypeptides and enzyme preparations containing them, which enhance the efficiency of the cellulosic degradation even at elevated temperatures. The polypeptides are produced by recombinant technology, and means for their production are described. The novel polypeptides are useful in processing biomass, and in biofuel, starch, textile, detergent, pulp and paper, food, feed or beverage industries. They may also be used e.g. in cleaning the interior of a dishwashing machine or for biofinishing or biostoning. The novel polypeptides are also useful in animal feed.

Abstract: The present invention relates to methods, kits, probes, and systems for distinguishing between nucleotide variants that are close in proximity on a gene. The methods, kits, probes, and systems can include the use of a small amplicon assay in combination with two unlabeled probes in a high resolution thermal melting analysis of a biological sample containing a locus of interest in order to discern between disease-causing and benign variants that are close in proximity on a gene within the biological sample. The present invention also relates to method of detecting a disease in a patient based on the patient's genotype by determining whether the patient has a disease-causing variant at a locus of interest. The signature melt curves produced by the unlabeled probe tests can be analyzed using HRMA software to distinguish between disease-causing and benign variants that are close in proximity on a gene within the biological sample.

Abstract: The present teachings relate to the extraction of nucleic acid from solid materials. Provided are useful compositions, methods and kits for obtaining nucleic acids from a solid biological sample or an adhesive material having a biological material adherent or embedded within the adhesive substrate. The extracted nucleic acid can be used in downstream applications such as genotyping, detection, quantification, and identification of the source of the biological material.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumor, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumor, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumor, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer.

Abstract: Described herein are methods, systems, compositions and kits to enable determination of a level of degradation of nucleic acids in a sample. For example, the determination of the amount of degradation of RNA in a sample can be accomplished by labeling one or both of the intact 5?- and/or 3?-ends of an mRNA molecule by taking advantage of the unique diol moiety present at these structures. Labeled nucleotides can then be partitioned into droplets and the amount of degradation can be determined by detecting label present in the partitions and making quantitative or qualitative comparisons with a reference sample. In some cases, the degree of degradation is also determined by factoring in the total concentration or quantity of RNA in the sample.

Abstract: The disclosure relates to a peptide (SEQ ID NO: 5), the use of said peptide for the treatment of the symptoms associated with pain, the use of said peptide for the inhibition of the activity of influenza virus and a pharmaceutical composition containing the peptide.

Abstract: The present invention relates to a process to perform a molecular risk assessment (MRA) upon a sample suspected to contain an enterohemorrhagic Escherichia coli (EHEC), comprising the steps: contacting said sample or DNA isolated therefrom with a pair of primers derived from the following target genes stx1, stx2, eae and/or espk; wherein the process is characterized in that if amplification products are detected for each of the target genes in the first step, in a second step said sample or DNA isolated therefrom is contacted with a pair of primers derived from the following target genes nleB, nleH1-2, nleE, ent/espL2, eae subtypes ?, ?, ? and ? and the target genes rfbE (0157), wbdl (0111), wzx (026); ihp1 (0145), wzx (0103); and detecting the presence or the absence of an amplification product for each of the target genes.

Abstract: The present invention provides systems, methods, and compositions for performing molecular tests. In particular, the present invention provides methods, compositions and systems for generating target sequence-linked solid supports (e.g., beads) using a solid support linked to a plurality of capture sequences and capture primers composed of a 3? target-specific portion and a 5? capture sequence portion. In certain embodiments, the target sequence linked solid support is used in sequencing methods (e.g., pyrosequencing, zero-mode waveguide type sequencing, nanopore sequencing, etc.) to determine the sequence of the target sequence (e.g., in order to detect the identity of a target nucleic acid in sample).

Abstract: This invention relates to a method for producing a protein of interest, comprising introducing an expression vector which comprises a gene fragment comprising a DNA encoding the protein of interest and a selectable marker gene and also comprises a pair of transposon sequences at both terminals of the gene fragment, into a suspension mammalian cell; integrating the gene fragment inserted between the pair of transposon sequences into a chromosome of the mammalian cell; obtaining a suspension mammalian cell producing the protein of interest; and suspension-culturing the suspension mammalian cell, and a suspension mammalian cell which expresses the protein of interest by the method.

Abstract: A method of detecting a target nucleic acid in a test sample utilizes a learning statistical classifier system to build a general linear classifier based on an amplification-dependent parameter for the target and the control nucleic acids, in order to classify the test sample as containing or not containing the target nucleic acid.

Abstract: The present application relates to detection units and methods for detecting one or more target analytes in a sample. In certain embodiments, the detection unit provides a first and second surface connected by a filament which is capable of binding the target analyte in the sample. In other embodiments, the detection unit provides a circular molecule capable of binding the target analyte and accumulating torsional stress in the presence of a twisting agent. The methods provide for the detection of the target analyte through the generation of a detectable signal following the binding of the target analyte to the filament.

Abstract: The present invention concerns methods and compositions for diagnosing and/or treating vascular diseases including cancer, cardiac diseases, vascular diseases of the eye, and inflammatory diseases. The methods involve measuring the levels of one or multiple miRNAs in patient samples and using the test results to diagnose and/or predict an optimal treatment regimen for the patient. Compositions described in the invention include nucleic acids that function as miRNAs or miRNA inhibitors that can be introduced to a patient to reduce or increase vascularization as needed.

Abstract: In one aspect, the invention provides methods of identifying genetic mutations that are associated with peripheral neurological disease. The methods comprise identifying a difference between a nucleic acid sequence of a small integral protein of the lysosome/late endosome (“SIMPLE”) gene from a mammalian subject exhibiting peripheral neuropathy and a nucleic acid sequence of a SIMPLE gene from a subject which is not exhibiting peripheral neuropathy, wherein the difference is a genetic mutation associated with peripheral neurological disease. In another aspect, isolated nucleic acid molecules encoding SIMPLE missense mutations are provided. In another aspect, a method of screening a subject to determine if the subject has a genetic predisposition to develop Charcot-Marie-Tooth type 1C neuropathy is provided. In another aspect, the invention provides kits for determining susceptibility or presence of Charcot-Marie-Tooth type 1C neuropathy in a mammalian subject.